Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-PSMA-617 |
| Synonyms | |
| Therapy Description |
225Ac-PSMA-617 is a 225Ac-labeled PSMA-targeting ligand that may inhibit growth of PSMA-expressing tumors (PMID: 27390158). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-PSMA-617 | AAA817|[225Ac]Ac-PSMA-617|Actinium Ac 225 vipivotide tetraxetan | 225Ac-PSMA-617 is a 225Ac-labeled PSMA-targeting ligand that may inhibit growth of PSMA-expressing tumors (PMID: 27390158). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06855277 | Phase III | Cabazitaxel Docetaxel Enzalutamide 225Ac-PSMA-617 + Abiraterone 225Ac-PSMA-617 Abiraterone 225Ac-PSMA-617 + Enzalutamide | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst) | Recruiting | USA | GBR | AUS | 7 |
| NCT06780670 | Phase II | 225Ac-PSMA-617 | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (PSMAcTION) | Recruiting | USA | ISR | BRA | AUS | 5 |